IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression

Figure 6 Expression of FBXO32 and its interaction with IGF2BP3 in gastric cancer. A: Expression of FBXO32 messenger RNA (mRNA) in gastric cancer (GC) cell lines and GES-1 as detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR); B: Expression of FBXO32 mRNA in 34 pairs of GC paired tissues as detected by qRT-PCR; C: Basal expression of FBXO32 protein in cell lines as detected by western blot (WB); D: Expression of FBXO32 protein in 19 pairs of GC paired tissues was detected by immunohistochemistry, scale bar: 50 μm; E: QRT-PCR was used to detect FBXO32 mRNA expression after IGF2BP3 knockdown in HGC-27 cells; F: WB was used to detect FBXO32 protein expression after IGF2BP3 knockdown in HGC-27 cells; G: QRT-PCR was used to detect FBXO32 mRNA expression after IGF2BP3 overexpression in MKN7 cells; H: WB was used to detect FBXO32 protein expression after IGF2BP3 overexpression in MKN7 cells. Data are presented as the mean ± SD. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. mRNA: Messenger RNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; siNC: Small interfering RNA-negative control; siIGF2BP3: Small interfering RNA-IGF2BP3; NS: Not significant.